Clinical Trial: Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Brief Summary: The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.

Detailed Summary: As a secondary objective, this study also aims to establish the corneal and anterior chamber concentration of ranibizumab when delivered subconjunctivally at the limbus in patients undergoing corneal transplantation. The effects of ranibizumab on corneal epithelial healing will be examined following adjunctive use in corneal transplantation. Finally, clinical characteristics including recurrent corneal neovascularization will be studied.
Sponsor: Bascom Palmer Eye Institute

Current Primary Outcome: The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation. [ Time Frame: 2 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: This study also aims to establish the corneal and anterior chamber concentration of ranibizumab when delivered subconjunctivally. The effects of ranibizumab on corneal epithelial healing and prevention of recurrent neovascularization will be examined. [ Time Frame: 2 years ]

Original Secondary Outcome: Same as current

Information By: Bascom Palmer Eye Institute

Dates:
Date Received: October 7, 2008
Date Started: October 2008
Date Completion:
Last Updated: July 24, 2012
Last Verified: July 2012